XM does not provide services to residents of the United States of America.

FX options reveal the true risk of more JPY intervention



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>BUZZ-COMMENT-FX options reveal the true risk of more JPY intervention</title></head><body>

June 25 (Reuters) -USD/JPY is threatening to retest the 160.24 peak which initiated the first of two bouts of official intervention on April 29 and May 1, but price action in forward-looking JPY-related FX options is different this time.

When USD/JPY eventually broke above the prior intervention peak from October 2022 at 151.94 on April 10, 2024, there was a big reaction in FX option markets. Implied volatility traded significantly higher and its premium for JPY calls over puts, the right to buy JPY versus sell it, followed suit. There was also a surge in demand for outright JPY call options that would protect against any sharp, intervention-driven USD/JPY drop.

The benchmark 1-month expiry USD/JPY implied volatility increased significantly from 7.8 to 11.7 between the 152.00 break on April 10, to the intervention-led drop from 160.25 on April 29. One-month expiry 25 delta risk reversals saw their JPY call over put implied volatility premium increase from 0.5 to 1.9.

This time however, USD/JPY implied volatility gains are less significant. The 1-month expiry contract is up from 7.5 to 9.1 over the last week (now 8.6). But, most importantly, downside risk premiums on risk reversals have actually fallen. In fact, the 1-month USD/JPY 25 delta risk reversal is around the 0.6 setback lows posted after the last intervention had already taken place.

The positive USD/JPY spot/implied volatility correlation, combined with a current lack of implied volatility premium/demand for JPY calls over puts on risk reversals, would suggest two things. 1. There's limited fear of a sudden USD/JPY drop (intervention). 2. The market is more wary of increased FX volatility/further FX gains if USD/JPY can break above the prior intervention peak.


For more click on FXBUZ












USD/JPY 1-month expiry FXO implied volatility https://tmsnrt.rs/4eCM5KD

1-month USD/JPY 25 delta risk reversal https://tmsnrt.rs/45F3sqg

(Richard Pace is a Reuters market analyst. The views expressed are his own)

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.